Inozyme announced that the FDA has granted Fast Track designation to INZ-701 for the treatment of ABCC6 Deficiency. ABCC6 Deficiency is a progressively debilitating condition of the vasculature and soft tissue that is estimated to affect approximately 1 in 25,000 to 1 in 50,000 individuals worldwide. In April, the company announced positive topline safety and immunogenicity data from its ongoing Phase 1/2 trial of INZ-701 in adults with ABCC6 Deficiency.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
- Inozyme initiated with an Overweight at Wells Fargo
- Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
- Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
- Inozyme expects cash to fund operations into Q4 of 2025
Questions or Comments about the article? Write to editor@tipranks.com